Vivoryon Secures U.S. Composition Of Matter Patent For Varoglutamstat, Adds To Intellectual Property Portfolio

Vivoryon Therapeutics N.V., a clinical-stage biopharmaceutical company developing small molecule medicines to modulate the activity and stability of disease-related proteins, has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent for its lead candidate, varoglutamstat. This patent was issued following an accelerated examination process and further strengthens the company’s intellectual property position around its lead compound.

The newly granted patent (US 12,312,335) covers the specific polymorph of the salt form used in Vivoryon’s drug product formulation of varoglutamstat, a first-in-class inhibitor targeting QPCT/L. The composition of matter patent is set to remain in force until 2044, with the possibility of a patent term extension of up to five additional years under the Hatch-Waxman Act, potentially extending protection through 2049.

In recent months, Vivoryon has also filed multiple patent applications related to kidney disease, its key area of focus. These filings cover various aspects of varoglutamstat and its analogues, including their medical use and dosing strategies. The applications extend to both monotherapy and combination approaches with existing standard-of-care treatments, particularly SGLT-2 inhibitors. These patent applications cover the free base form as well as all salt forms of varoglutamstat and are currently under examination.

The company continues to build a comprehensive and multi-layered intellectual property portfolio for QPCT/L inhibition. This includes patents covering composition of matter, medical uses, disease indications, and dosing regimens. Among the most recent additions are patent filings that relate to the treatment of kidney diseases, where varoglutamstat has shown a synergistic effect when used alongside SGLT-2 inhibitors in preclinical studies. These studies demonstrated significant potential with both once-daily and twice-daily treatment schedules.

Frank Weber, MD, CEO of Vivoryon, mentioned, “Vivoryon pursues a diligent and comprehensive strategy to continuously strengthen the intellectual property protecting our key assets on multiple levels. This successful patent application demonstrates our strong commitment to protecting the innovation of our lead asset varoglutamstat and is an important milestone for Vivoryon. The fact that it has been granted several months ahead of the anticipated timing is a testament to the outstanding work of our team. We expect that this long patent runway will support our efforts to maximize the full therapeutic potential of varoglutamstat, which we plan to develop in kidney disease.”

Vivoryon’s broader IP portfolio spans more than 20 patent families and includes over 400 patent applications and granted patents across major global markets. The majority of these patents relate to the composition of matter for QPCT/L inhibitors. The company remains focused on developing therapies for a wide range of serious diseases with high unmet medical needs, including kidney diseases, inflammatory conditions, cancer, and fibrotic and genetic disorders. With this newly granted U.S. patent and ongoing patent filings, Vivoryon continues to strengthen its position in the field and advance its strategy to deliver innovative treatments.